In the BioHarmony Drug Report Database

"Preview" Icon

Encorafenib

Braftovi (encorafenib) is a small molecule pharmaceutical. Encorafenib was first approved as Braftovi on 2018-06-27. It is used to treat melanoma in the USA. It has been approved in Europe to treat colorectal neoplasms and melanoma. Braftovi’s patents are valid until 2033-08-05 (FDA).

 

Trade Name

 

Braftovi
 

Common Name

 

encorafenib
 

ChEMBL ID

 

CHEMBL3301612
 

Indication

 

colorectal neoplasms, melanoma
 

Drug Class

 

Raf kinase inhibitors

Image (chem structure or protein)

Encorafenib structure rendering